BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) Director Jack Bendheim Sells Shares
What Happened
Jack Bendheim, a director and reported 10% owner of Phibro Animal Health Corporation (PAHC), sold a total of 14,080 shares in open-market transactions on February 19–20, 2026 for aggregate proceeds of approximately $715,775. Transactions reported:
- 7,040 shares on 2026-02-19 at a weighted avg price of $50.26 — proceeds $353,808 (prices ranged $49.965–$50.935).
- 6,643 shares on 2026-02-20 at a weighted avg price of $51.38 — proceeds $341,337 (prices ranged $50.90–$51.89).
- 397 shares on 2026-02-20 at a weighted avg price of $51.96 — proceeds $20,630 (prices ranged $51.92–$52.06).
All disposals are sales (code S) and were effected pursuant to a Rule 10b5-1 trading plan.
Key Details
- Transaction dates: Feb 19, 2026 (7,040 shares); Feb 20, 2026 (6,643 and 397 shares).
- Reported total proceeds: ~$715,775.
- Price reporting: weighted-average prices; per-footnote ranges provided for the individual trades. The filing offers to provide breakdowns by price on request.
- Holdings: some reported securities are held directly by BFI Co., LLC (a vehicle Mr. Bendheim controls and for which he disclaims beneficial ownership except to the extent of pecuniary interest); some securities are directly held by Mr. Bendheim per the filing.
- Plan: Sales were made under a 10b5-1 trading plan adopted by BFI on May 30, 2025.
- Timeliness: Form 4 was filed 2026-02-23 for trades on Feb 19–20, 2026 (timely under the two-business-day reporting rule).
- Shares owned after the transactions: not disclosed in the provided excerpt.
Context
These were planned open-market sales under a pre-established 10b5-1 plan by a 10% owner/director — a common mechanism for scheduled dispositions. Sales are routine disclosures and do not, by themselves, indicate management sentiment about the company’s outlook.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-02-19$50.26/sh−7,040$353,808→ 29,640 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-02-20$51.38/sh−6,643$341,337→ 22,997 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-02-20$51.96/sh−397$20,630→ 22,600 total(indirect: See)
Holdings
- 16,840
Class A Common Stock
[F6]
Footnotes (6)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.965 to $50.935. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $51.89.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.92 to $52.06.
- [F6]The reported securities are directly held by Jack Bendheim.